Beigene Co. Ltd. and Duality Biologics (Suzhou) Co. Ltd. have signed an agreement for Beigene to acquire an exclusive option for a global clinical and commercial license to a preclinical antibody-drug conjugate (ADC) therapy for select solid tumors.
Bruton tyrosine kinase (BTK) is involved in cell proliferation and survival in B-cell malignancies. Both covalent and noncovalent BTK inhibitors are in place, but their clinical benefit may be limited due to acquired BTK mutations.
During two different panels at Biocom California’s Global Life Science Partnering & Investor Conference, executives from a variety of pharmaceutical companies laid out their wants and needs in the current market environment. Large drug companies have relied on biotech companies to build out their pipelines for many years, but the level of outside inventions has been increasing over the last few years.
Beigene Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently linked to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety reported to be useful for the treatment of cancer.
